Holen Sie sich die Stockscreener-App
1.85
4.64%
-0.09
Schlusskurs vom Vortag:
$1.94
Offen:
$2
24-Stunden-Volumen:
41,727
Relative Volume:
0.30
Marktkapitalisierung:
$4.02M
Einnahmen:
$10.48M
Nettoeinkommen (Verlust:
$-37.74M
KGV:
-0.1143
EPS:
-16.1846
Netto-Cashflow:
$-29.03M
1W Leistung:
-9.76%
1M Leistung:
-15.53%
6M Leistung:
-85.75%
1J Leistung:
-93.02%
1-Tages-Spanne:
$1.80
$2.00
1-Wochen-Bereich:
$1.80
$2.10
52-Wochen-Spanne:
$1.5701
$33.25
Jaguar Health Inc Stock (JAGX) Company Profile
Firmenname
Jaguar Health Inc
Sektor
Branche
Telefon
415-371-8300
Adresse
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Vergleichen Sie JAGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
1.85 | 7.19M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-07-11 | Eingeleitet | Rodman & Renshaw | Buy |
Jaguar Health Inc Aktie (JAGX) Neueste Nachrichten
Has Jaguar Health Inc. formed a bullish divergenceEarnings Risk Summary & Growth Focused Stock Reports - newser.com
Short interest data insights for Jaguar Health Inc.2025 Buyback Activity & Daily Profit Focused Screening - newser.com
Jaguar Health Inc. stock trendline breakdownJuly 2025 Summary & Precise Trade Entry Recommendations - newser.com
How hedge fund analytics apply to Jaguar Health Inc. stockAnalyst Downgrade & Weekly High Momentum Picks - newser.com
Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition - The Marion Star
News impact scoring models applied to Jaguar Health Inc.Market Activity Report & Smart Swing Trading Techniques - newser.com
Is Jaguar Health Inc. showing signs of accumulationQuarterly Market Summary & Community Consensus Trade Alerts - newser.com
Live market analysis of Jaguar Health Inc.Earnings Performance Report & Real-Time Chart Breakout Alerts - newser.com
Is Jaguar Health Inc. stock attractive for passive investorsJuly 2025 Volume & Growth Focused Stock Reports - newser.com
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Palm Beach Daily News
Will Jaguar Health Inc. benefit from macro trendsJuly 2025 News Drivers & Technical Analysis for Trade Confirmation - newser.com
Will Jaguar Health Inc. stock pay special dividendsWeekly Trade Analysis & Accurate Technical Buy Alerts - newser.com
How to use Fibonacci retracement on Jaguar Health Inc.Watch List & Free Expert Verified Stock Movement Alerts - newser.com
How dovish Fed policy supports Jaguar Health Inc. (1JA0) stockJuly 2025 Setups & High Conviction Investment Ideas - newser.com
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts - Shelby Star
FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease - Lubbock Avalanche-Journal
Can Jaguar Health Inc. stock surprise with earnings upsideQuarterly Trade Summary & Weekly Sector Rotation Insights - newser.com
Published on: 2025-10-28 08:23:49 - fcp.pa.gov.br
Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders - Corpus Christi Caller-Times
Finanzdaten der Jaguar Health Inc-Aktie (JAGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):